Cargando…
Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis
Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152260/ https://www.ncbi.nlm.nih.gov/pubmed/35656294 http://dx.doi.org/10.3389/fphar.2022.823530 |
_version_ | 1784717607635517440 |
---|---|
author | Gou, Wen-Jun Zhou, Fa-Wei Providencia, Rui Wang, Bo Zhang, Heng Hu, Shou-Liang Gao, Xiao-Li Tuo, Yan-hong Zhang, Yong Li, Tian |
author_facet | Gou, Wen-Jun Zhou, Fa-Wei Providencia, Rui Wang, Bo Zhang, Heng Hu, Shou-Liang Gao, Xiao-Li Tuo, Yan-hong Zhang, Yong Li, Tian |
author_sort | Gou, Wen-Jun |
collection | PubMed |
description | Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020120143). The meta-analysis revealed that MRA significantly reduced all-cause mortality (ACM) and cardiovascular mortality (CVM). Patients receiving MRA presented improved left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF), decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP). There was no significant difference in the serum potassium level between the MRA group and the placebo group. MRA vs. control exerts definite survival and cardiovascular benefits in dialysis patients, including reducing all-cause mortality and cardiovascular mortality, LVMI, and arterial blood pressure, and improving LVEF. In terms of safety, MRA did not increase serum potassium levels for dialysis patients with safety. Systematic Review Registration: (https://inplasy.com/inplasy-protocol-1239-2/), identifier (INPLASY2020120143). |
format | Online Article Text |
id | pubmed-9152260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91522602022-06-01 Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis Gou, Wen-Jun Zhou, Fa-Wei Providencia, Rui Wang, Bo Zhang, Heng Hu, Shou-Liang Gao, Xiao-Li Tuo, Yan-hong Zhang, Yong Li, Tian Front Pharmacol Pharmacology Whether Mineralocorticoid receptor antagonists (MRA) reduce mortality and cardiovascular effects of dialysis patients remains unclear. A meta-analysis was designed to investigate whether MRA reduce mortality and cardiovascular effects of dialysis patients, with a registration in INPLASY (INPLASY2020120143). The meta-analysis revealed that MRA significantly reduced all-cause mortality (ACM) and cardiovascular mortality (CVM). Patients receiving MRA presented improved left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF), decreased systolic blood pressure (SBP) and diastolic blood pressure (DBP). There was no significant difference in the serum potassium level between the MRA group and the placebo group. MRA vs. control exerts definite survival and cardiovascular benefits in dialysis patients, including reducing all-cause mortality and cardiovascular mortality, LVMI, and arterial blood pressure, and improving LVEF. In terms of safety, MRA did not increase serum potassium levels for dialysis patients with safety. Systematic Review Registration: (https://inplasy.com/inplasy-protocol-1239-2/), identifier (INPLASY2020120143). Frontiers Media S.A. 2022-05-17 /pmc/articles/PMC9152260/ /pubmed/35656294 http://dx.doi.org/10.3389/fphar.2022.823530 Text en Copyright © 2022 Gou, Zhou, Providencia, Wang, Zhang, Hu, Gao, Tuo, Zhang and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Gou, Wen-Jun Zhou, Fa-Wei Providencia, Rui Wang, Bo Zhang, Heng Hu, Shou-Liang Gao, Xiao-Li Tuo, Yan-hong Zhang, Yong Li, Tian Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis |
title | Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis |
title_full | Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis |
title_fullStr | Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis |
title_full_unstemmed | Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis |
title_short | Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis |
title_sort | association of mineralocorticoid receptor antagonists with the mortality and cardiovascular effects in dialysis patients: a meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152260/ https://www.ncbi.nlm.nih.gov/pubmed/35656294 http://dx.doi.org/10.3389/fphar.2022.823530 |
work_keys_str_mv | AT gouwenjun associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT zhoufawei associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT providenciarui associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT wangbo associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT zhangheng associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT hushouliang associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT gaoxiaoli associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT tuoyanhong associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT zhangyong associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis AT litian associationofmineralocorticoidreceptorantagonistswiththemortalityandcardiovasculareffectsindialysispatientsametaanalysis |